ArticleBMC microbiology2025
Surveillance and characterization of carbapenem-resistant Enterobacter cloacae complex from China, 2015-2018.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular epidemiology and antimicrobial resistance of extended-spectrum beta-lactamases-producingJAC-antimicrobial resistance · 2026Article
- A New Challenge of Antibiotic-Resistant Bacteria: Carbapenem-ResistantMicroorganisms · 2026Review
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe carbapenem-resistant Enterobacter cloacae (CREC) have become a global health concern. However, our understanding of its epidemiological trends and resistance mechanisms still needs to be improved.
methodsNinety-one non-repetitive clinical CREC isolates were collected from 12 hospitals across China and identified using MALDI-TOF MS, rMLST, ANI, MASH, and dDDH. Minimal inhibitory concentrations were determined via broth microdilution. Resistance genes and plasmid replicons were identified using ResFinder and PlasmidFinder. Carbonyl cyanide 3-chlorophenylhydrazone suppression test and OmpC and OmpF overexpression test were conducted on 32 non-carbapenemase-producing (NCP) isolates. A phylogenetic tree was constructed with kSNP4 and visualized through iTOL.
resultsAmong the 91 CREC isolates, E. hormaechei was predominate (75 isolates), followed by E. kobei (five isolates). Within E. hormaechei, E. hormaechei subsp xiangfangensis was the most widespread subspecies. Sixty isolates produced carbapenemase, with bla
conclusionsAmong CREC in China, the bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.